These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 20575820)

  • 1. Buprenorphine and carbamazepine as a treatment for detoxification of opiate addicts with multiple drug misuse: a pilot study.
    Schneider U; Paetzold W; Eronat V; Huber TJ; Seifert J; Wiese B; Emrich HM
    Addict Biol; 2000 Jan; 5(1):65-9. PubMed ID: 20575820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone.
    Seifert J; Metzner C; Paetzold W; Borsutzky M; Passie T; Rollnik J; Wiese B; Emrich HM; Schneider U
    Pharmacopsychiatry; 2002 Sep; 35(5):159-64. PubMed ID: 12237786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone.
    Seifert J; Metzner C; Paetzold W; Borsutzky M; Ohlmeier M; Passie T; Hauser U; Becker H; Wiese B; Emrich H; Schneider U
    Addict Biol; 2005 Jun; 10(2):157-64. PubMed ID: 16191668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of polydrug-using opiate dependents during withdrawal: towards a standardisation of treatment.
    Kristensen Ø; Lølandsmo T; Isaksen A; Vederhus JK; Clausen T
    BMC Psychiatry; 2006 Nov; 6():54. PubMed ID: 17107609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Detoxification of poly-substance abusers with buprenorphine. Effects on affect, anxiety, and withdrawal symptoms].
    Paetzold W; Eronat V; Seifert J; Holze I; Emrich HM; Schneider U
    Nervenarzt; 2000 Sep; 71(9):722-9. PubMed ID: 11042867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid detoxification using high doses of buprenorphine in 24 hours: a randomized, double blind, controlled clinical trial.
    Assadi SM; Hafezi M; Mokri A; Razzaghi EM; Ghaeli P
    J Subst Abuse Treat; 2004 Jul; 27(1):75-82. PubMed ID: 15223097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Buprenorphine as a new alternative for detoxification of heroin addicts. It causes only mild withdrawal problems, abating quickly].
    Blennow G; Fergusson A; Medvedeo A
    Lakartidningen; 2000 Apr; 97(15):1830-3. PubMed ID: 10815411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients?
    Reed LJ; Glasper A; de Wet CJ; Bearn J; Gossop M
    J Clin Psychopharmacol; 2007 Apr; 27(2):188-92. PubMed ID: 17414244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, double-dummy, randomized, prospective pilot study of the partial mu opiate agonist, buprenorphine, for acute detoxification from heroin.
    Oreskovich MR; Saxon AJ; Ellis ML; Malte CA; Reoux JP; Knox PC
    Drug Alcohol Depend; 2005 Jan; 77(1):71-9. PubMed ID: 15607843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment completion on an inpatient detoxification unit: impact of a change to sublingual buprenorphine-naloxone.
    Soeffing JM; Rastegar DA
    J Subst Abuse Treat; 2007 Dec; 33(4):401-4. PubMed ID: 17400414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study.
    Stuppaeck CH; Pycha R; Miller C; Whitworth AB; Oberbauer H; Fleischhacker WW
    Alcohol Alcohol; 1992 Mar; 27(2):153-8. PubMed ID: 1524606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid addicts at admission vs. slow-release oral morphine, methadone, and sublingual buprenorphine maintenance treatment participants.
    Giacomuzzi S; Kemmler G; Ertl M; Riemer Y
    Subst Use Misuse; 2006; 41(2):223-44. PubMed ID: 16393744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of patients with moderately severe methadone dependence onto buprenorphine.
    Glasper A; Reed LJ; de Wet CJ; Gossop M; Bearn J
    Addict Biol; 2005 Jun; 10(2):149-55. PubMed ID: 16191667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Buprenorphine or methadone for detoxification of young opioid addicts?].
    Ebner R; Schreiber W; Zierer C
    Psychiatr Prax; 2004 Nov; 31 Suppl 1():S108-10. PubMed ID: 15570521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a transdermal buprenorphine formulation in opioid detoxification.
    Lanier RK; Umbricht A; Harrison JA; Nuwayser ES; Bigelow GE
    Addiction; 2007 Oct; 102(10):1648-56. PubMed ID: 17854341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Buprenorphine abuse: high dose intravenous administration of buprenorphine].
    Varescon I; Vidal-Trécan G; Nabet N; Boissonnas A
    Encephale; 2002; 28(5 Pt 1):397-402. PubMed ID: 12386540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
    Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
    Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Well-being, psychosocial factors, and side-effects among heroin-dependent inpatients after detoxification using buprenorphine versus clonidine.
    Ponizovsky AM; Grinshpoon A; Margolis A; Cohen R; Rosca P
    Addict Behav; 2006 Nov; 31(11):2002-13. PubMed ID: 16524668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.